Nanjing Norman: Leading the Revolution in Immunodiagnostics and Shining at Medlab Middle East 2025

      From February 3 to 6, 2025, the 24th Medlab Middle East grandly opened at the Dubai World Trade Centre, gathering over 800 renowned in vitro diagnostics companies from more than 40 countries around the globe. As the annual global event for laboratory equipment, the exhibition served as an important platform for showcasing cutting-edge technology and innovative ideas. In this dynamic environment, Nanjing Norman Biotechnology Co., Ltd. made a stunning debut with its rapid chemiluminescence platform, NORMAN-CL211, reflecting its disruptive and pioneering spirit, and quickly became one of the exhibition’s highlights. 

·Technological Innovation Sets the Industry Benchmark

Nanjing Norman has always been committed to technological innovation in the field of outpatient and emergency testing, fully aware that time is critical in urgent care and emergency diagnostics. To address this need, the company developed a desktop rapid chemiluminescence immunodiagnostic platform that not only offers a compact design and user-friendly operation but also represents a significant technological breakthrough. The platform supports both rapid and conventional testing modes. In the rapid mode, the reaction time between reagents and samples is shortened to just 7 minutes, making it directly applicable to whole blood testing. This eliminates the need for traditional centrifugation, effectively reducing the precious time from blood collection to report generation and thereby providing emergency patients with additional crucial “golden” time.

·Attention to Detail, Caring for Every Patient

In today’s era of diversified emergency testing requirements, Nanjing Norman has introduced customized solutions tailored for different populations. For infants and young children, who often face challenges with blood collection, the company has developed a capillary blood diagnostic product that reduces the sample volume to just 10-20 microliters. A single capillary blood draw is sufficient to complete the entire inflammatory panel. This design not only eases the blood collection process for infants but also provides warmth and reassurance to parents, reflecting the company’s commitment to patient-centric social responsibility.

·Comprehensive Coverage to Meet Multi-Tiered Needs

Under conventional testing modes, the NORMAN-CL211 platform offers comprehensive coverage of immunodiagnostic projects with over 140 available tests. Whether it is for outpatient and emergency testing in large general hospitals or routine testing requirements in smaller hospitals and third-party diagnostic laboratories, the platform delivers precise and efficient results. With its differentiated competitive advantages and robust technological foundation, Nanjing Norman continues to drive industry development through innovation, setting new standards in diagnostics.

·International Stage, Shaping the Future Together

At Medlab Middle East 2025, Nanjing Norman’s booth attracted hundreds of new and returning customers from around the world. The company’s expert team provided detailed on-site explanations of its technical highlights and product advantages, while also exploring future deep-cooperation opportunities with numerous international partners. This major event not only showcased Nanjing Norman’s leadership in rapid immunodiagnostics but also laid a solid foundation for the company’s overseas business expansion in 2025.

·Pioneering Progress, Achieving a Bright Tomorrow

Nanjing Norman has always adhered to its corporate philosophy of “Self-driven, Self-reflective, Customer First,” and is dedicated to integrating technological achievements into everyone’s life. Looking ahead, the company will continue to leverage innovation as its driving force, offering efficient and precise testing services to customers worldwide and injecting new vitality into the field of emergency diagnostics. Let us all look forward to Nanjing Norman furthering its brilliant journey on the international medical testing stage and contributing more wisdom and strength to global health.